LSHHIGH SIGNALFINANCIAL10-K

LSH underwent massive business expansion into pharmaceutical distribution while experiencing severe cash burn deterioration and dramatic share count increases.

The company more than doubled its outstanding shares from 7.5M to 17.4M while net losses exploded from -$225K to -$5.2M, indicating potential dilutive financing to fund aggressive expansion. The addition of a new pharmaceutical distribution segment through Hupan Pharmaceutical represents a fundamental business model shift that investors must carefully evaluate for execution risk and capital requirements.

Comparing 2025-10-14 vs 2024-09-30View on EDGAR →
FINANCIAL ANALYSIS

Despite cash position improving dramatically from $124K to $5.0M, the company's financial health deteriorated significantly with operating cash flow worsening nearly 50x to -$2.7M and net losses expanding over 20x to -$5.2M. Total assets grew 57% to $14.4M while current liabilities increased 64% to $9.7M, suggesting rapid business expansion funded through equity dilution. The massive increase in share buybacks to $805K alongside deteriorating profitability presents a concerning capital allocation picture for a cash-burning growth company.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-4849.7%
-$54K→-$2.7M

Operating cash flow fell 4849.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+3911.4%
$124K→$5.0M

Cash position surged 3911.4% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
-2229%
-$225K→-$5.2M

Net income declined 2229% — review whether driven by operations, interest costs, or non-recurring items.

Share Buybacks
Cash Flow
+1594.2%
$48K→$805K

Share repurchases increased 1594.2% — management returning capital, signals confidence in intrinsic value.

Operating Income
P&L
-842.7%
-$526K→-$5.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Stockholders Equity
Balance Sheet
+344.8%
$640K→$2.8M

Equity base grew 344.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+190.4%
$3.5M→$10.3M

Current assets grew 190.4% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+172.4%
$18K→$50K

Capital expenditure jumped 172.4% — major investment cycle underway; assess returns on deployment.

Current Liabilities
Balance Sheet
+64%
$5.9M→$9.7M

Current liabilities surged 64% — significant near-term obligations; verify ability to meet short-term debt.

Total Assets
Balance Sheet
+56.7%
$9.2M→$14.4M

Asset base grew 56.7% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2025-10-14
PRIOR — 2024-09-30
ADDED
As of October 10, 2025, the Registrant had 17,427,559 shares of common stock issued and outstanding.
Form 10-K Summary 36 Signatures 37 i EXPLANATORY NOTE As used in this Annual Report on Form 10-K, unless otherwise indicated or the context otherwise requires, references to: Lakeside, the Company, we, us, and our refer to Lakeside Holding Limited together with its consolidated subsidiaries; ABL refer to American Bear Logistics Corp.
Sichuan Hupan refer to Sichuan Hupan Jincheng Enterprise Management Co., Ltd., a PRC limited liability company in China and a wholly owned subsidiary of Lakeside; Hupan Pharmaceutical refer to Hupan Pharmaceutical (Hubei) Co., Ltd., a PRC limited liability company in China and a wholly owned subsidiary of Sichuan Hupan; RMB and Renminbi refer to the legal currency of China; US$, U.S.
dollars, $, and dollars refer to the legal currency of the United States.
For the year ended June 30, 2025, we also operate a new business segment through Hupan Pharmaceutical, a comprehensive pharmaceutical distribution and supply chain service provider headquartered in Wuhan, China with verticals in brand promotion and healthcare technology support.
+7 more — sign up free →
REMOVED
The Registrant s shares of common stock began trading on June 28, 2024.
As of September 25, 2024, the Registrant had 7,500,000 shares of common stock issued and outstanding.
Form 10-K Summary 36 Signatures 37 i EXPLANATORY NOTE As used in this Annual Report on Form 10-K, unless otherwise indicated or the context otherwise requires, references to Lakeside, the Company, we, us, and our refer to Lakeside Holding Limited together with its consolidated subsidiaries.
Since inception and as of June 30, 2024, we had served over 300 customers to fulfill over 41,000 cross-border supply chain solution orders.
Since inception and as of June 30, 2024, we had collaborated with almost all major global ocean and air carriers to forward over 31,300 twenty-foot equivalent unit, or TEU, of container loads and 47,800 tons of air cargo.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →